The legalisation of medical cannabis in November 2018 was hailed as a landmark victory for the British medical industry, with scientists, researchers and patients alike all welcoming the ch
The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia.
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio